| Autor: |
Carrera‐Martínez, Monserrat, Mora‐García, María de L., García‐Rocha, Rosario, Weiss‐Steider, Benny, Montesinos‐Montesinos, Juan J., Hernández‐Montes, Jorge, Don‐López, Christian A., Monroy‐García, Alberto |
| Předmět: |
|
| Zdroj: |
Cell Biochemistry & Function; Apr2023, Vol. 41 Issue 3, p321-330, 10p |
| Abstrakt: |
Recently, a link between the biological activity of CD73 in solid tumors and multidrug resistance protein (MRP) has been proposed. Cisplatin (CP) is the most widely used anticancer agent to treat advanced and recurrent cervical cancer (CC). However, multidrug resistance protein‐1 (MRP1) is overexpressed in approximately 85% of these tumors and has been strongly associated with cisplatin resistance (CPR). In this study, we examine the involvement of CD73 and the interaction of adenosine (ADO) with its receptors (ARs) in MRP1 expression in CC cells. We found that ADO positively modulates MRP1 expression in CC cells in a dose‐dependent manner. The inhibition of CD73 expression with a CD73‐targeted siRNA and A2AR blockade with the selective antagonist ZM241385 significantly decreased MRP1 expression and the extrusive capacity of CC cells, making them significantly more sensitive to CP treatment than cancer cells treated with MK‐751, a specific MRP1 inhibitor. These results suggest CD73 inhibition or blocking ADO signaling through A2AR could be strategies to reverse CPR in patients with advanced or recurrent CC, which is characterized by very low response rates to CP (10%–20%). Significance Statement: This study provides the first evidence to show that the inhibition of CD73 or blocking ADO signaling through A2AR negatively modulates MRP1 expression in CC cells, increasing their sensitivity to CP treatment. This finding may have clinical significance as a therapeutic target for reversing CPR in patients with advanced or recurrent CC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text